BeOne Medicines Ltd. (688235.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	33.0B	38.2B	27.2B	17.4B	9.6B
Cost of Revenue	3.7B	4.7B	4.2B	2.7B	1.9B
Gross Profit	29.2B	33.5B	23.0B	14.7B	7.7B
Operating Expenses
R&D Expense	12.6B	15.5B	14.1B	12.8B	11.2B
SG&A Expense	593.2M	—	—	—	—
General & Admin Expense	3.5B	4.4B	4.3B	3.5B	2.7B
Selling & Marketing Expense	8.1B	10.6B	8.9B	7.3B	6.0B
Other Expenses	—	—	—	—	—
Total Operating Expenses	25.4B	30.9B	27.5B	23.9B	21.2B
Cost and Expenses	29.2B	35.6B	31.8B	26.5B	23.1B
Operating Income (EBIT)	3.9B	2.6B	(4.2B)	(8.8B)	(13.4B)
Non-Operating
Interest Income	27.9M	—	—	—	—
Interest Expense	39.7M	—	—	—	—
Net Interest Income	(11.8M)	—	—	—	—
Other Non-Op Income/Expense	(12.6M)	—	—	—	—
Non-Operating Income (excl Interest)	(27.2M)	—	—	—	—
EBT (Pre-Tax Income)	3.9B	2.6B	(4.2B)	(6.2B)	(13.4B)
Income Tax Expense	1.1B	1.1B	815.6M	507.6M	215.1M
Bottom Line
Net Income	2.9B	1.5B	(5.0B)	(6.7B)	(13.6B)
Earnings from Cont. Ops	2.9B	1.5B	(5.0B)	(6.7B)	(13.6B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	2.9B	1.5B	(5.0B)	(6.7B)	(13.6B)
Per Share
Basic EPS	CN¥27.04	CN¥1.03	(CN¥3.64)	(CN¥4.95)	(CN¥10.18)
Diluted EPS	CN¥26.65	CN¥0.98	(CN¥3.64)	(CN¥4.95)	(CN¥10.18)
Revenue Per Share	CN¥295.37	—	—	—	—
Shares
Basic Shares Outstanding	111.6M	—	—	—	—
Diluted Shares Outstanding	115.8M	—	—	—	—
Profitability Metrics
EBITDA	392.7M	3.6B	(2.9B)	(8.2B)	(13.0B)
D&A	40.5M	1.0B	1.2B	651.2M	459.5M
EBIT	352.2M	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026